Drug Interactions between Linzess and sotorasib
This report displays the potential drug interactions for the following 2 drugs:
- Linzess (linaclotide)
- sotorasib
Interactions between your drugs
No interactions were found between Linzess and sotorasib. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Linzess
A total of 59 drugs are known to interact with Linzess.
- Linzess is in the drug class guanylate cyclase-C agonists.
- Linzess is used to treat the following conditions:
sotorasib
A total of 503 drugs are known to interact with sotorasib.
- Sotorasib is in the drug class miscellaneous antineoplastics.
- Sotorasib is used to treat the following conditions:
Drug and food interactions
linaclotide food
Applies to: Linzess (linaclotide)
ADJUST DOSING INTERVAL: Administration of linaclotide in the fed condition resulted in more gastrointestinal side effects and more frequent and looser stools, than when it was administered under fasting conditions.
MANAGEMENT: It is recommended to take linaclotide 30 minutes before a meal.
References (2)
- EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
- (2012) "Product Information. Linzess (linaclotide)." Forest Pharmaceuticals
sotorasib food
Applies to: sotorasib
Food does not appear to have a clinically significant effect on the oral bioavailability of sotorasib. When a 960 mg dose of sotorasib was administered to study patients with a high-fat, high-calorie meal (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively), sotorasib peak plasma concentration (Cmax) did not change while systemic exposure (AUC 0-24 hours) increased by 25% compared to administration under fasted conditions. Sotorasib can be administered with or without food at approximately the same time each day.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2021) "Product Information. Lumakras (sotorasib)." Amgen USA
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.